Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Jacob L. van Dam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6947-9035; OpenAlex author ID A5087659165. Sources: OpenAlex.

Their work

Papers
25 (first author 10, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
94
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 4 papers · 2022: 5 papers · 2023: 2 papers · 2024: 2 papers · 2025: 6 papers · 2026: 5 papers

Papers 25

  1. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. First author DOI 10.1016/s1470-2045(25)00729-6↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… First author DOI 10.1093/jnci/djag033↗
  4. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  5. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  6. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  7. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  8. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… First author DOI 10.1016/s1470-2045(25)00363-8↗
  9. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  10. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  11. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  12. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  13. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. First author DOI 10.1200/jco.23.01311↗
  14. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… First author DOI 10.1093/bjs/znad210↗
  15. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  16. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Co-author DOI 10.1016/j.ejca.2021.10.023↗
  17. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. First author DOI 10.1093/jnci/djac018↗
  18. Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. First author DOI 10.1155/2022/8549487↗
  19. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… First author DOI 10.1200/jco.21.02233↗
  20. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. First author DOI 10.6004/jnccn.2022.7008↗
  21. Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer: Pathological Assessment and Recurrence Patterns. Co-author DOI 10.1097/mpa.0000000000001897↗
  22. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreati… Co-author DOI 10.1186/s12885-021-08031-z↗
  23. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  24. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. First author DOI 10.1245/s10434-021-10276-8↗
  25. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 18 shared papers, 2018–2026 · strength 2.68
  2. Marc G. Besselink · 17 shared papers, 2018–2026 · strength 2.58
  3. Casper H.J. van Eijck · 16 shared papers, 2018–2026 · strength 2.32
  4. Quisette P. Janssen · 12 shared papers, 2021–2026 · strength 2.00
  5. Johanna W. Wilmink · 11 shared papers, 2021–2026 · strength 1.73
  6. Marjolein Y.V. Homs · 11 shared papers, 2021–2026 · strength 1.73
  7. Geertjan van Tienhoven · 10 shared papers, 2021–2026 · strength 1.58
  8. Bert A. Bonsing · 8 shared papers, 2021–2026 · strength 1.11
  9. Esther N. Dekker · 6 shared papers, 2023–2026 · strength 1.08
  10. Hjalmar C. van Santvoort · 7 shared papers, 2021–2026 · strength 1.03
  11. Ignace H. J. T. de Hingh · 7 shared papers, 2021–2026 · strength 1.00
  12. Alice Chia-Chi Wei · 6 shared papers, 2021–2026 · strength 0.88
  13. Gijs A. Patijn · 6 shared papers, 2021–2026 · strength 0.87
  14. Roeland F. de Wilde · 5 shared papers, 2021–2026 · strength 0.85
  15. Marion B.M. van der Kolk · 5 shared papers, 2021–2026 · strength 0.77
  16. Eva M M Verkolf · 4 shared papers, 2023–2026 · strength 0.69
  17. Matthew H. G. Katz · 4 shared papers, 2022–2026 · strength 0.68
  18. Amer H. Zureikat · 4 shared papers, 2022–2026 · strength 0.68
  19. Laura R. Prakash · 4 shared papers, 2022–2026 · strength 0.68
  20. Ching-Wei David Tzeng · 4 shared papers, 2022–2026 · strength 0.68
  21. Judith de Vos‐Geelen · 5 shared papers, 2021–2025 · strength 0.61
  22. Thomas F. Stoop · 3 shared papers, 2024–2026 · strength 0.55
  23. Deesje Doppenberg · 4 shared papers, 2022–2024 · strength 0.54
  24. Joost J.M.E. Nuyttens · 4 shared papers, 2021–2025 · strength 0.50
  25. Sebastiaan Festen · 3 shared papers, 2022–2026 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.